Carlos Sanchez, M.D.
About Carlos Sanchez, M.D.
Carlos Sanchez, M.D. is an Assistant Professor of Neurosurgery and Pediatrics with extensive experience in pediatric neurosurgery and research. He has held various academic and clinical positions, including roles at prestigious institutions such as Massachusetts General Hospital and Children's National Hospital.
Work at The George Washington University
Carlos Sanchez, M.D. serves as an Assistant Professor of Neurosurgery and Pediatrics at The George Washington University since 2018. In addition to his teaching role, he is also a Neuro-Oncology and Pediatric Neurosurgeon at The George Washington University Hospital. He has been involved in research as a Principal Investigator at the GW Cancer Center since 2021.
Education and Expertise
Carlos Sanchez, M.D. holds a Bachelor of Science in Biology from the University of Vermont, completed in 1999. He earned his Doctor of Medicine degree from SGU School of Medicine in 2004. He furthered his education with a year of study in Physiology and Biophysics at Georgetown University in 2000. Additionally, he completed a Post-Doctoral Fellowship in Brain Tumor Immunotherapy at Harvard University from 2005 to 2010.
Background
Carlos Sanchez, M.D. has a diverse professional background in neurosurgery. He began his medical career with a residency in the Department of Neurosurgery at The University of New Mexico from 2010 to 2015. He has held various positions in prestigious institutions, including Massachusetts General Hospital and Children's National Hospital, where he served as Director of Skull Base Surgery from 2019 to 2021.
Achievements
Carlos Sanchez, M.D. has contributed to the field of pediatric neurosurgery through various roles, including serving as a National Research Scholar Award Fellow at Massachusetts General Hospital from 2005 to 2009. He has been a Fellow in Pediatric Neurosurgery at Rady Children's Hospital-San Diego from 2017 to 2018. Currently, he serves as a consultant for the FDA's Cellular Tissue and Gene Therapies Advisory Committee since 2021.